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Abstract
Introduction: Low copy number (CN) of the Fc gamma receptor 3B (FCGR3B) gene has been associated with
systemic autoimmune disease. This receptor for IgG is present almost exclusively on neutrophils and plays a role in
their interaction with immune complexes. At present the relationship between FCGR3B and rheumatoid arthritis
(RA) is unclear. The aim of the present study was to investigate whether low CN of the FCGR3B gene is associated
with susceptibility to RA.
Method: The FCGR3B CN was determined using a custom Taqman® CN assay (Hs04211858; Applied Biosystems,
Foster City, CA, USA) in 197 RA patients, recruited from a tertiary setting, and in 162 population matched controls.
Odds ratios for low CN (< 2) and high CN (> 2), both relative to the normal diploid 2CN, were estimated by
logistic regression.
Results: A significant association between RA and low FCGR3B CN was observed, with frequencies of 13.7% in RA
patients compared with 6.2% in controls (odds ratio 2.5, 95% confidence interval 1.2 to 5.4, P = 0.017). No
association was observed between low CN and the presence of rheumatoid factor, anti-cyclic citrullinated peptide
antibodies or radiographic erosions in RA patients. A meta-analysis including six previous studies confirmed an
association between RA and low FCGR3B CN (odds ratio 1.47, 95% confidence interval 1.13 to 1.92, P = 0.004).
Conclusions: The present study confirms that a low CN of the FCGR3B gene is associated with susceptibility to RA.
The association may be stronger in patients recruited from a tertiary setting, which may relate to disease severity
and/or complications. The mechanism of susceptibility remains unclear and further study is required.
Introduction
Variation in the copy number (CN) of genes within the
human genome is an important source of genetic varia-
tion, and is defined as a sequence of DNA > 1 kb pre-
sent in altered CN when compared with a reference
genome [1]. In the diploid human genome, autosomal
genes are normally present in two copies (one on each
chromosome). When copy number variation (CNV) is
present, however, the number of copies can vary from
zero to greater than two. Studies have demonstrated a
large number of genes within the human genome that
display CNV in a relatively high frequency. CNV may be
a major source of quantitative variation in expression,
and has been proposed to contribute to phenotypic
diversity and disease susceptibility [2-4]. There are
increasing reports of associations between CNV of cer-
tain genes, coding for various components of the
immune system, and autoimmune diseases such as
Crohn’s disease [5], rheumatoid arthritis (RA) [6], sys-
temic lupus erythematosis (SLE) [7], Sjögren’s syndrome
[8], and psoriasis [9].
Fc gamma receptors are present predominantly on
myeloid cells and interact with the Fc portion of the
IgG molecule. They can be either stimulatory or inhi-
bitory and play an integral role in the identification
and destruction of both endogenous and foreign
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opsonised material. A number of subtypes have been
identified with extensive structural diversity leading to
differences in binding capacity, signal transduction
pathways and cell-type surface expression [10]. The Fc
gamma receptor 3B (FCGR3B) gene is a stimulatory
receptor that is present almost exclusively on the sur-
face of neutrophils. Its precise function in the immune
system remains to be clarified but there is accumulat-
ing evidence that it plays a role in the interaction
between immune complexes and neutrophils [11-13].
CNV has been well characterised in the Fc gamma
receptor region (Chr 1q23-24) [14], and a low CN of
FCGR3B has been associated with SLE and Sjögren’s
syndrome [7,15,16] as well as with RA [17]. The evi-
dence to date for an association between low CN and
RA has been contradictory, with studies showing both
the presence and absence of a significant relationship
[15,17,18]. The aim of our study was to determine
whether there is an association between CN of the
FCGR3B gene and RA, compared with population con-
trols. The identification of such a relationship and con-
firmation of a low CN of FCGR3B as a susceptibility
factor would contribute to our evolving understanding
of the pathogenesis of RA.
Materials and methods
Study subjects
The study sample included 197 patients recruited from
the rheumatology outpatient services at The Queen Eli-
zabeth Hospital and the Royal Adelaide Hospital, two
tertiary-level hospitals in South Australia. All subjects
had been diagnosed with RA according to the 1987
American College of Rheumatology criteria for RA [19].
Recruitment of patients and DNA extraction occurred
over the period of 2006 to 2011. Clinical characteristics
including gender, rheumatoid factor (RF) and anti-cyclic
citrullinated peptide (anti-CCP) antibody status and the
presence or absence of erosive disease were collected.
The presence of erosive disease was defined on the basis
of radiographs, formally reported by a radiologist, show-
ing evidence of erosions, at any articular site, consistent
with a diagnosis of RA. The designation of no erosive
disease required formal bilateral hand and feet radio-
graphs reported as showing no evidence of erosions.
Adequate radiographic data were available in 139
patients (71%). The control group included 162 popula-
tion-based Caucasian healthy subjects (53% female,
median age 56 years).
The study was conducted in accordance with the
Declaration of Helsinki and approved by the Central
North Adelaide Health Service Ethics of Human
Research Committee. All participants provided
informed, written consent.
Determination of FCGR3B copy number
The FCGR3B CN was determined from genomic DNA
using a custom Taqman® CN real-time, quantitative
PCR assay (Hs04211858, FAM-MGB dual-labelled
probe; Applied Biosystems, Foster City, CA, USA) with
RNase P (4403326, VIC-TAMRA dual-labelled probe;
Applied Biosystems) as the reference assay, performed
as a duplex reaction. The assay was performed accord-
ing to the manufacturer’s instructions and quantitative
PCR reactions were run on an Applied Biosystems 7300
Real Time PCR machine. All samples were tested in tri-
plicate, and fluorescence signals were normalised to
ROX.
The TaqMan® quantitative PCR assay was initially
validated against an alternative, end-point PCR paralo-
gue ratio (single primer pair) assay, which estimates
FCGR2C CN relative to FCGR2A, as previously
described [16]. The rationale for this is that several stu-
dies have reported complete agreement (that is, linkage
disequilibrium) between FCGR2C CN and FCGR3B CN
[14,16]. The amount of PCR product corresponding to
each gene was quantified by measuring respective peak
heights in the QIAxel capillary electrophoresis system
(Qiagen, Hilden, Germany), and CN assignments were
performed following cluster analysis of the log ratio of
the peak heights. We tested 100 samples in parallel, and
following independent analysis there was complete con-
cordance in CN assignment for 99 of these samples; for
the remaining sample, CN could not be unequivocally
assigned by the paralogue ratio assay results, and was
not retested.
The TaqMan® assay quantitative PCR amplification
curves were analysed using three different quantitation
points (Cq): Ct (autobaseline), 0.2 cycle threshold, as
recommended by the manufacturer); Cy0, determined
from a five-parameter log-logistic curve analysis from
the ΔRn data [20]; and CpD1, derived from a six-para-
meter log-logistic curve (which explicitly models the
baseline) from the Rn data. Cy0 and CpD1 estimates
were obtained using the R project statistical computing
qpcR library [21,22]. Analysis was performed on a plate-
by plate basis, and the CN was assigned from the raw
Cq values using CopyCaller™ software (version 1.0;
Applied Biosystems). This software employs a clustering
algorithm and assigns the cluster with the most samples
as 2CN. Reference samples of 1CN, 2CN and 3CN (vali-
dated using the paralogue ratio assay) were included on
each plate to ensure that the most frequent CN cate-
gories were represented on each plate, and to confirm
consistency in correct CN assignment between plates.
The CopyCaller™ software also provides extensive
diagnostics for the validity of the results, which were
accepted only when confidence in discrete CN
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assignment was > 80%, the standard deviation of the
sample replicate ΔCq estimates was < 0.20, and a refer-
ence gene Cq was < 32. CN assignment for results that
failed any of these criteria was unequivocally resolved by
retesting. Although different, all three Cq estimates gave
discrete and identical CN assignments. An occasional
spuriously high CN (> 5) result was obtained via the
recommended Ct method however, due to sporadic
FAM auto-baselining problems. We observed no discre-
pancies with the Cy0 method. This method has been
reported to overcome quantitation inaccuracy in the
presence of amplification inhibition [20] so it is there-
fore unlikely that variability in DNA quality was a con-
founder in CN assignment, as has been previously
reported [17]. The CpD1 estimate (from unbaselined
data) consistently resulted in the lowest standard devia-
tion for replicate ΔCq estimates. Interestingly, the CpD1
estimate from baselined data did not perform well in
terms of discrete CN assignments (nor did the CpD2
estimate from either baselined or unbaselined data).
Both baselining and Cq estimation algorithms, which
differ between instrumentation and are generally not
reported, can therefore substantially influence the per-
formance of the assay.
Overall, our methodology resulted in clear assignment
of a discrete FCGR3B CN to each sample, as is evident
from the results for a sample plate depicted in Figure 1.
Statistical analysis
The distributions of FCGR3B CN between patients and
controls and between patients with and without RF,
anti-CCP and radiographic erosions were compared
using the maximum likelihood chi-square test with two
degrees of freedom. Logistic regression analysis was
used to calculate odds ratios (ORs) for low CN (< 2)
and high CN (> 2), both relative to the normal diploid
2CN for RA patients compared with controls. P < 0.05
was considered statistically significant. Analysis was per-
formed using Statistica version 6 (Statsoft, Tulsa, OK,
USA).
A random-effects meta-analysis of previously pub-
lished studies examining the relationship between low
CN of FCGR3B and RA was performed using the R
metafor library [21,23] and the restricted maximum-like-
lihood method.
Results
Of the 197 RA patients, 145 (74%) were female. Of
those for whom autoantibody status was determined,
136 (75%) were RF-positive and 68 (60%) were anti-
CCP-positive. Of those with adequate radiographic data,
96 (69%) had erosive disease.
The majority of patients in both groups had two
copies of the FCGR3B gene (75.6% in the RA cohort
and 85.8% in the controls). A higher frequency of low
FCGR3B CN (< 2) was observed in the RA patients
compared with controls (13.7% and 6.2%, respectively),
with OR 2.5 (95% confidence interval 1.2 to 5.4, P =
0.017) indicating an increased susceptibility for RA
being associated with a low CN. No significant differ-
ence was seen in the frequency of high CN (> 2)
between RA patients and controls (10.7% and 8%,
respectively; OR 1.5, 95% confidence interval 0.7 to 3.1,
P = 0.27) (Table 1).
No significant relationships were observed between
FCGR3B CN and RF, anti-CCP antibodies (Table 2) or
radiographic erosions (data not shown) within RA
patients.
An update of the meta-analysis for the association of
low FCGR3B CN (< 2) with RA, originally reported by
McKinney and colleagues [17], was also performed,
which included two subsequently published studies
[15,18] in addition to the current study. The meta-analy-
sis now includes data from seven RA cohorts, predomi-
nantly of Northern European Caucasians, totalling 2,475
RA patients and 2,320 controls. This meta-analysis con-
firms that low FCGR3B CN is a risk factor for RA (OR
1.47, 95% confidence interval 1.13 to 1.92, P = 0.004,
random-effects estimate), even though many individual
studies failed to reach statistical significance (Figure 2).
Further, the I2 value of 26% indicates that the studies
are relatively homogeneous.
Discussion
Low FCGR3B CN, while best characterised in SLE, has
been associated with a range of systemic autoimmune
diseases [7]. In our study we have demonstrated a signif-
icant association between low CN of the FCGR3B gene
and RA. Further, we have confirmed this association
with a meta-analysis that includes seven published
patient cohorts; while the association is relatively mod-
est and somewhat less than that reported for SLE (OR
1.47, 95% confidence interval 1.13 to 1.92), it is highly
significant (P = 0.004). This relatively modest effect size
may explain why individual, smaller studies have
reported inconsistent results.
We observed a relatively high effect size in our study.
Our RA patients were recruited from rheumatology out-
patient services in two large metropolitan tertiary cen-
tres, and therefore our cohort may be biased towards a
more severe, or refractory, disease phenotype, which is
reflected in the high incidence of seropositivity and ero-
sive disease. However, the association between low
FCGR3B CN and disease severity, or response to ther-
apy, remains to be evaluated.
Only one previous study has examined the relation-
ship between seropositivity and FCGR3B CN. McKinney
and colleagues observed a higher frequency of low CN
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in RF-negative patients, but this was not observed in all
cohorts. The anti-CCP status was available in only one
cohort and its relationship with CN was not analysed
[17]. In our patient group, we found no evidence for an
association between FCGR3B low CN and RF or anti-
CCP status nor the presence of erosive disease.
If the presence of a low FCGR3B CN increases the
susceptibility to RA then the function of this receptor
and how a low CN predisposes to the development of
autoimmune disease needs to be considered. Fc gamma
receptors can be either stimulatory or inhibitory in
terms of the effect the binding of IgG has on the
Figure 1 Analysis summary for a typical TaqMan® Fc gamma receptor 3B copy number assay plate. Analysis summary for a typical
TaqMan® Fc gamma receptor 3B (FCGR3B) gene copy number (CN) assay plate with one, two, three, and four CN samples using CpD1
quantitation point (Cq) estimates. (A) Bar chart output from the CopyCaller™ analysis software demonstrating that the continuous estimated CN
ratios for each sample form distinct clusters with values that are very close to integer values. Three reference samples are included on the plate.
The 3CN reference sample is second from the left, and the 1CN and 2CN reference samples are the second last and last (right), respectively. The
overall estimate of the standard deviation for replicate ΔCq values for this plate was 0.07. (B) Scatter plot of the ΔCq values versus the (natural)
log of the assigned CN. The straight line represents the fitted regression line and the dotted lines represent the 95% prediction intervals for the
regression. The intercept term for the regression analysis may vary between plates due to small differences in the pipetting of reagents. CN
assignment must therefore be performed on an individual plate basis.
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effector cell. FCGR3B is a stimulatory receptor that is
located predominately on the cell surface of neutrophils
[10].
The function of FCGR3B in the immune response has
been studied by a number of groups, with all evidence
suggesting this receptor plays a role in the interaction
between neutrophils and immune complexes [11,12].
Would a low genomic CN of the FCGR3B gene have an
effect on this? Willcocks and colleagues demonstrated a
clear correlation between CN and FCGR3B cell surface
expression, neutrophil adherence to IgG-coated surfaces
and immune complex uptake [13], suggesting that low
CN of the FCGR3B gene has physiological implications
in the neutrophil-immune complex interaction.
If FCGR3B plays a role in the adherence of neutro-
phils to immune complexes and their subsequent clear-
ance, then by what mechanism could a reduced CN
predispose to autoimmune disease? It is possible that
persistent immune complexes, due to ineffective clear-
ance, have the potential for promoting or exacerbating
autoimmunity. The lack of an association between low
FCGR3B CN and RF or anti-CCP in RA patients, how-
ever, suggests that this potentially impaired interaction
may not specifically involve autoantigen-immune com-
plexes. Another possibility is that an impaired response
to an infectious agent and delayed clearance could pro-
mote the breakdown of self-tolerance and the subse-
quent development of autoimmunity. There is some
evidence of a relationship between FCGR3B and sus-
ceptibility to infection to support this theory, but the
data are contradictory [16,24-26].
A reduction in FCGR3B density on the surface of neu-
trophils could disturb a delicate balance with the subse-
quent dominance of other Fc gamma receptors with
greater stimulatory activity and potential pathogenicity.
A study by Tsuboi and colleagues examined and com-
pared the function of FCGR2A and FCGR3B, both sti-
mulatory Fc gamma receptors [27]. Transgenic mice
expressing human FCGR2A and/or FCGR3B on neutro-
phils were challenged with immune complexes. Com-
pared with neutrophils expressing FCGR3B, neutrophils
expressing FCGR2A demonstrated significantly greater
adhesion to immune complexes and release of reactive
oxygen species. The mice with neutrophils expressing
FCGR2A developed an autoimmune nephritis with the
accumulation of glomerular neutrophils, interstitial
macrophages and CD4+ T cells, the development of
renal dysfunction and death. Clinical evidence of renal
disease was absent in FCGR3B-deficient mice, with his-
tology showing the accumulation of glomerular neutro-
phils with minimal interstitial leukocytic infiltrate and
no evidence of renal injury. These results suggest that
FCGR3B acts as a benign immune complex clearance
mechanism and that reduced expression may lead to
increased FCGR2A-immune complex interaction and
thus promote immune complex-mediated tissue damage.
Further support for this theory comes from evidence
that immune complexes containing citrullinated proteins
are potent stimulators of TNF production by macro-
phages via FCGR2A and are critical for the development
of immune-complex-mediated inflammatory arthritis in
murine models [28-30].
A final possibility is that FCGR3B CN is in linkage
disequilibrium with another functional variant in the Fc
gamma receptor region. For example, FCGR3B is adja-
cent to FCGR2C and the CNV of these two genes is in
complete linkage disequilibrium [31].
In the present study we have demonstrated that a low
CN of the FCGR3B gene is associated with RA. This
raises the question of what role a low CN may play in
the disease phenotype. The fact that we were able to
demonstrate a significant relationship in our cohort of
patients from a tertiary referral centre suggests that low
Table 1 Frequency of FCGR3B copy number variants in











< 2 27 (13.7%) 10 (6.2%) 2.5 (1.2 to 5.4) 0.017
2 149 (75.6%) 139 (85.8%) 1
> 2 21 (10.7%) 13 (8.0%) 1.5 (0.7 to 3.1) 0.27
Global test c2 = 6.9, degrees of freedom = 2, P = 0.031
Data presented as n (%). CI, confidence interval; CN, copy number; FCGR3B, Fc
gamma receptor 3B; RA, rheumatoid arthritis.
Table 2 Comparative frequency of FCGR3B copy number variants with rheumatoid factor and anti-cyclic citrullinated
peptide autoantibodies
FCGR3B CN Rheumatoid factor Anti-CCP
Positive Negative Positive Negative
< 2 19 (13.97%) 5 (11.11%) 7 (10.29%) 5 (10.87%)
2 106 (77.94%) 33 (73.33%) 52 (76.47%) 36 (78.26%)
> 2 11 (8.09%) 7 (15.56%) 9 (13.24%) 5 (10.87%)
Global test c2 = 2.03, degrees of freedom = 2, P = 0.363 c2 = 0.15, degrees of freedom = 2, P = 0.93
Comparative frequency of Fc gamma receptor 3B (FCGR3B) copy number (CN) variants in rheumatoid arthritis patients positive and negative for rheumatoid
factor and anti-cyclic citrullinated peptide (anti-CCP) autoantibodies. Data presented as n (%).
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CN may be associated with more severe or refractory
disease. Future research should explore these relation-
ships further as well as consider whether low FCGR3B
CN increases the risk of infection in the context of
immunosuppressive disease-modifying therapy.
Conclusions
While previous studies have reported inconsistent
results, the present study finds that a low CN of the
FCGR3B gene is associated with susceptibility to RA.
The mechanism of this increased susceptibility remains
unclear, although there are a number of potential possi-
bilities based upon the growing understanding of the
function of the FCGR3B receptor. Such knowledge
could potentially contribute to our understanding of the
complex pathogenesis of RA.
Abbreviations
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